Is HIPEC Surgery Dangerous? Risks and Complications

HIPEC surgery carries real risks, but its danger profile is comparable to, and in some ways better than, other major cancer operations that are widely considered standard of care. A large study comparing it head-to-head with procedures like the Whipple (for pancreatic cancer) and esophagectomy found that HIPEC’s 30-day mortality was about 1%, lower than any of those comparison surgeries. That said, roughly a third of patients experience some form of complication, and the procedure uniquely combines the stresses of extensive abdominal surgery with heated chemotherapy delivered directly into the open abdomen. Understanding the specific risks, who faces the highest odds of complications, and what recovery actually looks like matters when weighing this option.

What HIPEC Actually Involves and Why Risks Are Elevated

HIPEC stands for hyperthermic intraperitoneal chemotherapy. In practice, a surgeon first performs cytoreductive surgery, removing as many visible tumor deposits as possible from the lining of the abdominal cavity and, often, portions of affected organs. Once the abdomen is as clear as the surgeon can make it, heated chemotherapy is circulated directly through the abdominal cavity for 60 to 90 minutes, typically at inflow temperatures around 42–43°C. Patients face the usual physiological stresses of a major operation alongside the thermal stress of heated chemotherapy agents bathing their internal organs.¹ The combination of prolonged surgery, organ removal, and intraperitoneal drug exposure is what drives the complication rate.

Operations frequently last six hours or longer, and they can involve removing portions of the colon, small bowel, spleen, gallbladder, or even parts of the diaphragm. The more organs removed and the more extensive the disease spread, the higher the risk. This is not a single standardized procedure with a fixed scope; the amount of surgery involved varies enormously from one patient to the next, and so does the risk.

Overall Complication and Mortality Rates

The broadest outcome data comes from a large Italian registry of over 2,500 patients. The overall postoperative complication rate was 34%, and the mortality rate was 1.6%. About 9% of patients required a return trip to the operating room for a surgical complication.² The strongest predictors of complications in that dataset were the type of chemotherapy perfusion used, body mass index, and how many organ resections were performed. Age and number of resections were the strongest predictors of death.

A meta-analysis and systematic review reinforced these findings, identifying the extent of cancer spread within the abdomen (measured by the peritoneal cancer index), longer operative time, sex, and smoking as risk factors for postoperative complications.³ In short, the more disease is present and the longer the surgery takes, the more likely something goes wrong afterward.

How HIPEC Compares to Other Major Cancer Surgeries

One of the most useful pieces of evidence for putting HIPEC’s risks into perspective comes from a study that directly compared it against four other high-risk cancer operations: the Whipple procedure, esophagectomy, radical liver hepatectomy, and total abdominal hysterectomy with staging. The 30-day mortality for HIPEC was about 1.1%, which was lower than the Whipple (2.5%), radical liver hepatectomy (2.9%), esophagectomy (3.0%), and total staging hysterectomy (3.9%).⁴

Wound infection rates for HIPEC were also lower than or comparable to those of the other procedures. Organ-space infections after HIPEC ran around 7%, lower than the rates seen after radical liver resection, total staging hysterectomy, and the Whipple. The median hospital stay was about eight days, shorter than the Whipple or esophagectomy. This comparison matters because it places HIPEC firmly in the category of “major but not uniquely dangerous” among surgeries that cancer patients already undergo. HIPEC is not an outlier; it is a procedure with serious but manageable risk, on par with or better than what oncologic surgeons routinely perform.

Gastrointestinal Complications

The gut takes a beating during HIPEC. Surgeons often need to remove segments of bowel, and the combination of hyperthermia and concentrated chemotherapy can impair the normal healing process at intestinal connection sites. The most common and clinically significant gastrointestinal complications are small bowel perforations and anastomotic leaks, where a surgical reconnection fails to seal properly. Across large published case series, severe gastrointestinal complication rates range from roughly 5% to 19%.⁵

Patients who have had previous abdominal surgery face additional risk here. Scar tissue from prior operations distorts anatomy and makes dissection trickier, which has been linked to a higher rate of bowel fistulas. When a leak or perforation does happen, it usually means a return to the operating room, a prolonged hospital stay, and sometimes a temporary or permanent stoma (a surgically created opening for waste to leave the body).

Kidney Damage From Chemotherapy Drugs

One of the most specific risks of HIPEC, separate from the surgical component, is kidney injury caused by chemotherapy drugs absorbed from the abdominal cavity into the bloodstream. Cisplatin, a drug commonly used in HIPEC for ovarian and other cancers, is the main culprit. A retrospective study identified cisplatin-containing HIPEC regimens as an independent risk factor for acute kidney injury and recommended restricting cisplatin to cases where it has a proven advantage over other drugs.⁶

Cisplatin-related kidney toxicity can occasionally progress to chronic kidney failure, which is why researchers have been investigating protective drugs. Sodium thiosulfate, given intravenously before and after the HIPEC perfusion, appears to be effective at shielding the kidneys from cisplatin damage.⁷ A separate study examining cisplatin-based HIPEC for ovarian cancer confirmed that kidney toxicity is high enough with cisplatin to warrant routine use of nephroprotective agents.⁸ If you’re being considered for cisplatin-based HIPEC, it’s worth asking whether sodium thiosulfate is part of your center’s protocol.

Blood Clotting Abnormalities

HIPEC frequently disrupts the blood’s ability to clot normally, a complication that doesn’t get as much attention as gut leaks or kidney damage but is common enough to matter. A retrospective study found that some form of coagulopathy developed in 38% of patients, with severe coagulopathy in about 5%. Platelet counts dropped substantially in the first few days after surgery, and clotting times became prolonged.⁹

A more recent study that specifically compared patients who had cytoreductive surgery alone with those who also received HIPEC found that severe coagulopathy was roughly twice as common when HIPEC was added (about 21% versus 10%). The HIPEC component itself was an independent risk factor for severe clotting disturbances, along with significant blood loss during surgery.¹⁰ These clotting problems can lead to bleeding complications or the need for transfusions, and they require careful monitoring in the days after surgery.

Respiratory Problems and Pleural Effusions

Lung-related complications are a particular concern when tumor deposits on the diaphragm need to be stripped away. Removing the peritoneal lining of the diaphragm can injure the muscle and allow chemotherapy-laden fluid to cross into the chest cavity. In one study focused on patients who underwent diaphragmatic surgery, pleural effusions (fluid collections around the lungs) appeared on imaging in a large proportion, though only about 8% required drainage.¹¹ Diaphragm stripping and a high tumor burden within the abdomen were both identified as independent risk factors for respiratory complications.

Separately, systemic absorption of certain chemotherapy drugs used in HIPEC can cause drug-specific toxicities. Neutropenia, a dangerous drop in infection-fighting white blood cells, is the most common form of systemic drug toxicity from absorbed intraperitoneal chemotherapy.¹² In rare cases, drugs like mitomycin C have been linked to pulmonary toxicity. These systemic effects are generally dose-dependent and monitored closely in the postoperative period.

Infection After HIPEC

Infection is among the most common complications. In a study tracking 100 patients, 43% experienced some form of infectious complication, including surgical site infections, respiratory tract infections, urinary tract infections, and postoperative sepsis. The factors most strongly linked to infection were small bowel resection and the total number of organs removed.¹³ The high infection rate partly reflects the sheer scope of the operation and partly reflects the immunosuppressive effects of both the surgery itself and the chemotherapy.

Fifteen patients in that same series developed sepsis, a life-threatening infection response. Surgical site infections were the most frequent type, making up the majority of cases. The infection risk is one reason HIPEC patients typically stay in the hospital for a week or more and are monitored intensively during that period.

Does the Heat Itself Cause Harm?

One of the more intuitive concerns about HIPEC is whether bathing the internal organs in fluid heated to 42–43°C might cause dangerous overheating of the body. A study of 147 patients found that about two-thirds experienced some elevation in core body temperature during the perfusion phase, but average core temperature did not exceed 40°C. Patients who developed elevated core temperatures had similar postoperative complication rates, mortality, and cancer outcomes compared to those who stayed at normal body temperature, suggesting that the degree of systemic heating most patients actually experience is tolerable and does not independently worsen outcomes.¹⁴

Anesthesiologists play a critical role in managing temperature during HIPEC. They use active cooling measures and closely monitor hemodynamic status, including cardiac output and fluid balance. Goal-directed fluid therapy, where fluid administration is guided by real-time measures of how the heart and circulation are responding rather than by a fixed formula, has been shown to reduce postoperative complications.¹⁵ Careful fluid management during the perfusion phase also helps protect the kidneys.

How Hospital Experience Affects Your Risk

Where you have HIPEC done matters. Like other complex surgical procedures, outcomes are better at high-volume centers that perform the operation regularly. Centers with more experience have improved surgical proficiency and better systems for catching and managing complications early.¹⁶ This is a consistent finding across surgical oncology, not unique to HIPEC, but the complexity of the procedure makes it especially relevant. If you have any choice about where to be treated, this is one situation where seeking out a center that does a high volume of these cases is worth the inconvenience.

Open Versus Closed Technique

HIPEC can be delivered two ways: with the abdomen left open during the perfusion (the “coliseum” technique) or with the abdomen temporarily closed. Some surgeons and patients worry that one approach might be safer than the other. A comparison from a high-volume center found that the two methods had nearly identical complication rates. The incidence of any complication within 60 days was about 40% with both open and closed techniques, and severe complications occurred in roughly 13–14% of patients in each group. There was no perioperative mortality in either group.¹⁷ The choice between techniques appears to come down to surgeon preference and specific patient factors rather than a clear safety advantage for one approach.

What Recovery Actually Looks Like

The first few months after HIPEC are hard. Quality-of-life scores drop significantly in the weeks following surgery, with physical functioning, fatigue, and pain all worsening. In one study, patients hit their lowest point around one month after the operation. By 12 months, however, most functional scores and symptom measures had returned to near-baseline levels, though some patients had lingering cognitive or bowel disturbances.¹⁸

A Canadian study echoed this pattern: global health scores declined at three months but returned to near baseline by 12 months, and cognitive function actually improved by six months compared to preoperative levels.¹⁹ Another study tracking patients further found that physical and role functioning recovered by the time of a later follow-up period after an initial significant drop, with fatigue and pain following the same pattern of temporary worsening followed by recovery.²⁰

Longer-term data introduces a wrinkle, though. One study found that while quality of life rebounded to baseline around six months and held steady through 12 months, scores dipped again at 24 months.²¹ That later decline may reflect disease recurrence, the effects of additional treatments, or the cumulative toll of living with advanced cancer, rather than a delayed complication of HIPEC itself. But it’s a reminder that the recovery trajectory extends well beyond the immediate postoperative window.

When Patients Need a Second HIPEC

Some patients with recurrent peritoneal disease are offered a repeat cytoreductive surgery with HIPEC. The natural worry is that a second procedure on a previously operated and chemotherapy-treated abdomen would be considerably more dangerous. A multicentre Canadian study found that complication rates were essentially the same for first and second procedures: about 46% had a severe complication after their first surgery, and 43% after their second. There were no deaths within 30 days following either operation.²² Disease-free survival tended to be shorter after the second procedure, which reflects the biology of recurrent cancer more than the safety of the operation. The finding that complication rates held steady is reassuring for carefully selected patients being considered for redo surgery.